Nevrargenics Ltd.

Breakthrough in Motor Neurone Disease Research: Nevrargenics' Drug, Ellorarxine™, Shows Promise We are excited to share some incredible news that has just been published by Durham University. Our lead drug, Ellorarxine™, has demonstrated remarkable potential in treating Motor Neurone Disease (MND), as highlighted in a recent study published in the International Journal of Molecular Sciences. In collaboration with Durham's top-rated Chemistry department, researchers have shown that Ellorarxine™ addresses multiple underlying causes of MND, not just its symptoms. It stands apart in its ability to promote neuroprotection, neuroplasticity, and neurorepair – offering new hope for those affected by this devastating disease. Key findings from the study include: Antioxidant & Anti-inflammatory Effects: Even at very low concentrations, Ellorarxine™ demonstrated powerful effects in combating cellular stress. Promotion of Neurite Growth & Improved Mitochondrial Health: Crucial factors in the nervous system's ability to regenerate and protect itself. Crosses the Blood-Brain Barrier: An essential feature for effective neurodegenerative treatments, ensuring it reaches the spinal cord where MND takes its toll. We are now gearing up for human trials, having received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). This is a pivotal step in our journey to bring meaningful change to the lives of those suffering from MND. The study marks a significant milestone in our work, and we couldn’t be prouder of our collaboration with the brilliant researchers at Durham and Aberdeen Universities. If you’d like to read more about this exciting breakthrough, we encourage you to check out Durham University's full article here [https://lnkd.in/dxuXxUzC] and the published study in the International Journal of Molecular Sciences [https://lnkd.in/espTgAAg]. At Nevrargenics, our mission remains clear: to develop transformative treatments that target the root causes of neurodegenerative diseases. We are one step closer to achieving this, and we look forward to sharing our progress as we continue with trials for Ellorarxine™. Thank you to Durham University for your continued partnership in this important work. Together, we are paving the way for a brighter future in MND research and treatment. #nevrargenics #neurodegeneration #neurology #neuroscience #pharmaceuticals #innovation #drugdiscovery #drugdevelopment #biotech #als #ftd #mnd #alzheimers #multiplesclerosis #parkinsons #neuroprotection

Great to see DDW (https://lnkd.in/evPwhR7y) pick key new research that Nevrargenics is pleased to be involved with and proud to be collaborating with Aberdeen and Durham Universities, published in Frontiers in Neuroscience: https://lnkd.in/espTgAAg Nice work Azita, showing that Ellorarxine has condierable potential for the treatment of ALS from in vitro model studies!

The Unmet Need in Neurodegeneration: Reflections on Recent Developments in Alzheimer's Treatments Recent news about the MHRA's approval of Biogen and Eisai's Alzheimer’s drug, Leqembi (lecanemab), marks a significant milestone in the ongoing battle against neurodegenerative diseases. While this approval is a step forward, NICE's decision not to recommend the drug for use on the NHS highlights a critical issue: the ongoing challenge of balancing cost and effectiveness in drug development. As a company dedicated to the fight against neurodegeneration, we at Nevrargenics commend all efforts that push the boundaries of treatment for these devastating diseases. The approval of Leqembi by MHRA is a testament to the strides being made in the field, offering hope to those affected by Alzheimer's. However, the NICE decision underscores the importance of pursuing treatments that not only manage symptoms but also target the root causes of these conditions, delivering real value to patients. At Nevrargenics, our mission has always been to develop transformative treatments that go beyond symptom management. The recent approval for our lead drug, Ellorarxine™ (NVG645), by the MHRA to move into patient trials, is a significant step towards this goal. Unlike traditional treatments, Ellorarxine™ is designed to target the underlying causes of neurodegeneration, with a focus on conditions like Frontotemporal Dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS). The unmet need in neurodegenerative disease treatment is immense, and this is the driving force behind our work. As the world continues to search for more effective solutions, we remain committed to advancing drug development that not only slows down the progression of these diseases but also aims for a future where diseases like FTD and ALS can be effectively treated or even cured. Together, we continue to push forward in our mission to bring meaningful change to the lives of millions affected by neurodegenerative diseases. The need for bold, innovative approaches in drug development has never been clearer. We look forward to continuing this journey and to sharing our progress with you. #Alzheimers #Biogen #Eisai #Nice #NHS #Leqembi #Lecanemab #ALS #FTD #FrontoTemporalDementia #Nevrargenics #NeurodegenerativeDiseases #HopeForTheFuture #DrugDevelopment #NeurodegenerativeDiseases #Innovation #Neurodegeneration #Pharmaceuticals #Biotech https://lnkd.in/dvZtCx8Z

Empowering Hope: Nevrargenics Advances MND Treatment on World Motor Neurone Disease Awareness Month On the occasion of Motor Neurone Disease (MND) Awareness Month this June, we are thrilled to announce a major milestone in our journey towards developing new treatments for MND and related neurodegenerative conditions. We have received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) to commence clinical trials for our groundbreaking lead drug candidate. This represents a significant step forward in our mission to not only alleviate symptoms but also target the root causes of diseases like Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal dementia (FTD). What does this mean for patients? The trial will involve identifying participants who are willing to participate in testing our new drug. Administered via twice-weekly intravenous injections, the drug aims to promote neuroprotection, neuroplasticity and neurorepair (the 3 N’s), crucial for protecting neuronal cells and potentially reversing disease progression. Biomarker analysis and MRI imaging will assess the drug's efficacy in slowing, halting or reversing the diseases. Our research has shown promising results in preclinical models, where our drug successfully reversed various disease processes associated with neurodegeneration. We firmly believe that with dedication and innovation, a cure for MND is within reach. We are committed to pushing the boundaries of science and tackling the complex challenges of neurodegenerative diseases head-on. We invite you to learn more about our pioneering work and join us in our quest to make a meaningful impact on the lives of over one billion sufferers worldwide. Discover more about our CEO, Professor Andy Whiting, and the innovative research at Nevrargenics. Together, let's strive for breakthroughs that transform the future of healthcare. We extend our heartfelt thanks to Durham University for their unwavering support and for publishing the article highlighting our work at Nevrargenics in the fight against Motor Neurone Disease and other neurological conditions. https://lnkd.in/d69_nWnx #neurology #neurodegeneration #ALS #MND #FTD #treatment #drugdiscovery #drugdevelopment #Nevrargenics #pharmaceuticals #biotech

Revolutionising Neurodegenerative Disease Treatment: Insights from Nevrargenics Investor Presentation in London! We had an incredible opportunity to present Nevrargenics, our ground-breaking neuroscience company, at a prestigious event in London County Hall, right across from the iconic Big Ben and next to St Thomas's Hospital! Proudly hosted by Stakeholderz, the event brought together a dynamic group of investors eager to learn about our game-changing approach to neurodegenerative disease treatment. Neurodegenerative diseases affect over a billion people worldwide, imposing a significant human and economic burden. At Nevrargenics, we're on a mission to revolutionise the field with our cutting-edge technology, which is the result of 20 years of world-leading research conducted at Durham and Aberdeen Universities. Our lead drug candidate, based on our technology of modulating Retinoic Acid Receptors, has the potential to not only treat but also reverse neurodegenerative diseases through neurorepair - a truly unprecedented breakthrough! Backed by a vast intellectual property library, our approach represents a new era in drug development, offering immense promise for disruptive advancements in disease treatment. But we can't do it alone. We're seeking visionary investors to join us on this journey as we embark on the next phase of our development. We are now looking to secure $5m to fund manufacturing and trials for our lead drug, as well as the development of second-generation therapies. And the timing couldn't be better - Phase I/IIa trials have been green-lighted by the UK Regulator MHRA, meaning that human results will be available within a year, marking a potentially significant value creation and inflection point. What's more, Nevrargenics has already caught the attention of Big Pharma players, who will be our ultimate partners in drug development and commercialisation. From Westminster opposite the House of Parliament and on the river Thames, we're not just making waves in the industry - we're doing it with a view! Support Nevrargenics today and be part of the future of neurodegenerative disease treatment. Together, we can make a difference and transform lives around the world. #neuroscience #neurodegeneration #pharmaceuticals #biotechnology #drugs #als #ftd #parkinsons #alzheimers #ms #multiplesclerosis #neuroprotection #nevrargenics #research #drugdevelopment #treatment #therapy #clinical #trials